倍他乐克在扩张型心肌病的应用(2)
| 第1页 |
参见附件。
[2]Tigen K， Cevik C.β-blockers in the treatment of dilated cardiomyopathy： which is the best？ Curr Pharm Des， 2010， 16(26)： 2866-2871.
[3]世界卫生组织工作组.心肌病定义和分类.循环杂志， 1996 (93)：841-842.
[4]Puntmann VO， Ucar EA， Baydes RH， et al. Aortic Stiffness and Interstitial Myocardial Fibrosis by Native T1 Are Independently Associated With Left Ventricular Remodeling in Patients With Dilated Cardiomyopathy. Hypertension， 2014 ， 64(4)：762-768.
[5]Mahmud H， Silljé HH， Cannon MV， et al. Regulation of the(pro)renin-renin receptor in cardiac remodelling. J Cell Mol Med， 2012， 16(4)：722-729.
[6]Kroumpouzou E， Gomatos IP， Kataki A， et al. Common pathways for primary hypertrophic and dilated cardiomyopathy. Hybrid Hybridomics， 2003， 22(1)：41-45.
[7]Tanaka H， Matsumoto K， Sawa T， et al. Evaluation of global circumferential strain as prognostic marker after administration ofβ-blockers for dilated cardiomyopathy. Int J Cardiovasc Imaging， 2014， 30(7)：1279-1287.
[收稿日期：2014-08-26]
您现在查看是摘要介绍页，详见PDF附件。